Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Clinical trial NCT02089334 · TERMINATED
Trial details
- NCT number
- NCT02089334
- Sponsor
- Rexahn Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-08-01
- Primary completion
- 2018-04-26
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.